This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John M. A. Bohnen, MD, FRCSC; Robert A. Mustard, MD, FRCSC; B. Diana Schouten, RN

Arch Surg. 1994;129(1):33-38.

Abstract
Objective
To compare the outcome of abdominal infection in patients with or without previous systemic glucocorticoid therapy and to determine the effect of steroid administration on the relationship between APACHE II (Acute Physiology and Chronic Health Evaluation) scores and mortality.

Hypothesis
Steroid therapy leads to greater mortality and relatively lower APACHE II scores.

Design
Prospective cohort study.

Setting
University hospital.

Patients
Two hundred ninety-seven consecutive adult patients with abdominal infection treated by surgical or percutaneous drainage. Treatment was at the clinician's discretion. Seventy-one patients received systemic steroid therapy.

Outcome Measures
APACHE II score, clinical course, and death in hospital; relationship between APACHE II score and mortality in the steroid and no steroid groups.

Results
Thirty-three patients receiving steroid therapy (46%) died vs 55 (24%) of 226 patients not receiving steroid therapy. The APACHE II score (P<.0001) and steroid administration (P=.04) were each independently associated with death. Steroid-treated patients had the same probability of dying as "nonsteroid" patients with an APACHE II score a mean of 3.7 points higher (95% confidence limits, 0.03 and 7.7). The confidence that 2, 3, or 4 extra APACHE II points is the appropriate correction for steroid-treated patients is 80%, 60%, or 40%, respectively.

Conclusions
Patients receiving steroid therapy appear to be at higher risk of dying of abdominal infection than predicted by APACHE 11 scores. The number of patients receiving cancer chemotherapy was too small to determine whether this was an additional risk factor. In the design of clinical trials stratified by APACHE II scores, steroid-treated patients should either be excluded or assigned two extra APACHE II points.

(Arch Surg. 1994;129:33-38)

Author Affiliations
From the Department of Surgery, University of Toronto, and the Wellesley Hospital, Toronto, Ontario.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Molgramostim (GM-CSF) Associated With Antibiotic Treatment in Nontraumatic Abdominal Sepsis: A Randomized, Double-blind, Placebo-Controlled Clinical Trial.
Orozco et al.
Arch Surg 2006;141:150-153.
ABSTRACT | FULL TEXT  

Endogenous Cortisol Production in Response to Knee Arthroscopy and Total Knee Arthroplasty
Leopold et al.
JBJS 2003;85:2163-2167.
ABSTRACT | FULL TEXT  

APACHE II, POSSUM, and ASA Scores and the Risk of Perioperative Complications in Patients With Oral or Oropharyngeal Cancer
de Cassia Braga Ribeiro and Kowalski
Arch Otolaryngol Head Neck Surg 2003;129:739-745.
ABSTRACT | FULL TEXT  

Risk Factors for Postoperative Complications in Oral Cancer and Their Prognostic Implications
de Melo et al.
Arch Otolaryngol Head Neck Surg 2001;127:828-833.
ABSTRACT | FULL TEXT  

Surgical Infection Society--Trials and Tribulations: The Importance of Clinical Trials
Dellinger
Arch Surg 1998;133:1192-1197.
FULL TEXT